These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10050999)

  • 1. Antiemetic effects of Lerisetron in radiation-induced emesis in the dog.
    Gomez-de-Segura IA; Grande AG; De Miguel E
    Acta Oncol; 1998; 37(7-8):759-63. PubMed ID: 10050999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers.
    Cooper M; Sologuren A; Valiente R; Smith J
    Arzneimittelforschung; 2002; 52(9):689-94. PubMed ID: 12404884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment.
    LeBourgeois JP; McKenna CJ; Coster B; Feyer P; Franzén L; Goedhals L; Marzecki Z; Souhami L; Stewart A; Tønnessen F; Haigh C; Mitchell T; Wilkinson JR; Graham E
    Clin Oncol (R Coll Radiol); 1999; 11(5):340-7. PubMed ID: 10591823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
    Aapro M; Blower P
    Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
    Jeremić B
    Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experimental study of the role of blocking 5-HT3-receptors of serotonin and D2-receptors of dopamine in the mechanism of early radiation vomiting in dogs].
    Martirosov KS; Grigor'ev IuG; Borovkov MV; Zorin VV
    Radiats Biol Radioecol; 2002; 42(1):75-9. PubMed ID: 11898636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis.
    Haga K; Inaba K; Shoji H; Morimoto Y; Fukuda T; Setoguchi M
    Jpn J Pharmacol; 1993 Nov; 63(3):377-83. PubMed ID: 8107329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
    ; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J
    J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation.
    King GL; Rabin BM; Weatherspoon JK
    Aviat Space Environ Med; 1999 May; 70(5):485-92. PubMed ID: 10332945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escalating dose of oral ondansetron in the prevention of radiation induced emesis.
    Maisano R; Pergolizzi S; Settineri N
    Anticancer Res; 1998; 18(3B):2011-3. PubMed ID: 9677458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.
    Eglen RM; Lee CH; Smith WL; Johnson LG; Clark R; Whiting RL; Hegde SS
    Br J Pharmacol; 1995 Feb; 114(4):860-6. PubMed ID: 7773547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy.
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):619-25. PubMed ID: 10348292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
    Alon E; Biro P
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 May; 31(4):200-4. PubMed ID: 8704077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation.
    Sagrada A; Turconi M; Bonali P; Schiantarelli P; Micheletti R; Montagna E; Nicola M; Algate DR; Rimoldi EM; Donetti A
    Cancer Chemother Pharmacol; 1991; 28(6):470-4. PubMed ID: 1834359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum protein binding of lerisetron, a novel specific 5HT3 antagonist, in patients with cancer.
    Calvo R; Jiménez RM; Trocóniz IF; Suárez E; Gonzalo A; Lucero ML; Raczka E; Orjales A
    Cancer Chemother Pharmacol; 1998; 42(5):418-22. PubMed ID: 9771958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of serotonin antagonists for the control of chemotherapy-induced emesis.
    Hainsworth JD
    Semin Surg Oncol; 1993; 9(3):279-84. PubMed ID: 8516617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ondansetron, metoclopramide, and placebo in the prevention of postoperative emesis in children undergoing ophthalmic surgery.
    Bach-Styles T; Martin-Sheridan D; Hughes C; Kaufman S
    CRNA; 1997 Nov; 8(4):152-6. PubMed ID: 9437950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.